Ming Y. Lim
( out of 43 reviews )

Ming Y. Lim, MBBCh, MS

Languages spoken: English

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000

  • Dr. Ming Y. Lim is an Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders.

    Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves on the American Board of Internal Medicine Hematology Approval Committee and is the Chair of the American Society of Hematology Subcommittee on Stewardship and Systems-Based Hematology. She also serves on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates
    National Certification Board for Anticoagulation Providers

    Patient Rating

    5.0 /5
    ( out of 43 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    February 29, 2024
    SUGAR HOUSE HEALTH CENTER

    a compassionate dr , i have encountered many drs in my lifetime & she is the most compassionate of them all. Even her staffs takes time to help me in my refills, schedules, etc. The staffs are really getting good CME how to treat patients like they are your family.

    February 14, 2024
    SUGAR HOUSE HEALTH CENTER

    She is very nice and concerned about your health ,God bless her

    February 14, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Lim was very approachable, did a thoughtful assessment, and answered all of my questions. Very helpful.

    February 07, 2024
    SUGAR HOUSE HEALTH CENTER

    Very skilled and knowledgeable, and was quite open to options in setting up my care plan. Definitely an excellent choice for anyone seeking help with Hemophilia treatment.

    January 31, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Lim was very personable to talk to. She seems to have a very good understanding of the financial burden a prescription could put on the patient and suggested a way to proceed further without added burdens.

    January 27, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Lim is an excellent provider. She is specific in her diagnosis and treatment plans. But she couples that with compassion and true care for me as a person not just a patient.

    January 09, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Lim is great! She listens and explains thing really well. She doesn't talk down to you.

    January 09, 2024
    SUGAR HOUSE HEALTH CENTER

    Great doctor.

    December 13, 2023
    SUGAR HOUSE HEALTH CENTER

    Absolute gem of a human, would definitely recommend her to any bleeders out there!

    See More Patient Comments

  • Dr. Ming Y. Lim is an Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders.

    Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves on the American Board of Internal Medicine Hematology Approval Committee and is the Chair of the American Society of Hematology Subcommittee on Stewardship and Systems-Based Hematology. She also serves on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates
    National Certification Board for Anticoagulation Providers

    Education history

    Graduate Training Clinical Research - Medical University of South Carolina M.S.
    Hematology/Oncology - University of North Carolina at Chapel Hill School of Medicine Fellow
    Residency Internal Medicine - Mayo School of Graduate Medical Education Resident
    Palliative Medicine - Cardiff University School of Medicine Diploma
    Professional Medical Clinical Medicine - Cambridge University School of Clinical Medicine MB BChir
    Medical Sciences - Magdalene College, University of Cambridge M.A.

    Selected Publications

    Journal Article

    1. Lim MY, Rodgers GM, Branch DW, Simonsen SE (2024). Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single-institution cohort study. Haemophilia, 30(2), 470-477. (Read full article)
    2. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY (2023). A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv, 8(3), 620-623. (Read full article)
    3. Ragni MV, Callis J, Daoud N, Hu B, Manuel M, Santos J, Schwartz J, Friedman KD, Kouides P, Kuriakose P, Leavitt AD, Lim MY, Machin N, Recht M, Chrisentery-Singleton T (2023). Observational cohort study of long-term outcomes of liver transplantation in haemophilia. Haemophilia, 30(1), 87-97. (Read full article)
    4. Wheeler AP, Lim MY, Huguelet PS, Jaffray J, Staber JM, Funkhouser K, Carpenter SL, Weyand AC (2023). Trends in dedicated care for females with bleeding disorders within U.S. hemophilia treatment centers. Am J Hematol, 98(12), E399-E402. (Read full article)
    5. Cogan JC, McFarland MM, May JE, Lim MY (2023). Quality improvement approaches to heparin-induced thrombocytopenia: a scoping review. Res Pract Thromb Haemost, 7(7), 102219. (Read full article)
    6. Young A, Lim MY, Sanders J, Branch DW, Simonsen SE (2022). Pregnancy and Childbirth in Women with Bleeding Disorders: A Retrospective Cohort Study. Haemophilia, 29(1), 240-247. (Read full article)
    7. Bruno AM, Allshouse AA, Campbell HM, Branch DW, Lim MY, Silver RM, Metz TD (2022). Weight-Based Compared with Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol, 140(4), 575-583. (Read full article)
    8. Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA, United States Thrombotic Microangiopathies Consortium (2022). Race, Rituximab, and Relapse in TTP. Blood, 140(12), 1335-1344. (Read full article)

    Review

    1. Branch DW, Lim MY (2023). How I Diagnose And Treat Antiphospholipid Syndrome In Pregnancy. [Review]. Blood, 143(9), 757-768. (Read full article)
    2. Lim MY, Abou-Ismail MY, Branch DW (2022). Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. [Review]. Obstet Gynecol, 141(1), 85-108. (Read full article)
    3. Elshoury A, Schaefer JK, Lim MY, Skalla DP, Streiff MB (2022). Update on Guidelines for the Prevention of Cancer-Associated Thrombosis. [Review]. J Natl Compr Canc Netw, 1-8. (Read full article)
    4. Thomas VM, Abou-Ismail MY, Lim MY (2021). Off-label Use of Emicizumab in Persons with Acquired Haemophilia A and von Willebrand Disease: A Scoping Review of the Literature. [Review]. Haemophilia, 28(1), 4-17. (Read full article)
    5. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander NS (2021). Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. [Review]. J Natl Compr Canc Netw, 20(1), 91-95. (Read full article)
    6. Lim MY (2021). How Do We Optimally Utilize Factor Concentrates in Persons with Hemophilia? [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 206-214. (Read full article)

    Case Report

    1. Gleichgerrcht E, Lim MY, Turan TN (2017). Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia. Neurologist, 22(6), 241-244. (Read full article)

  • News & Podcasts